News

• Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
  02/25/2021 / 20:53 - GlobeNewswire
•  
• Genmab announces initiation of share buy-back program
  02/23/2021 / 17:05 - GlobeNewswire
•  
• Genmab Publishes 2020 Annual Report
  02/23/2021 / 17:00 - GlobeNewswire
•  
• Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines
  02/22/2021 / 14:00 - GlobeNewswire
•  
• Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
  02/10/2021 / 22:05 - GlobeNewswire
•  
• CHMP Issues Positive Opinion Recommending Ofatumumab in Relapsing Multiple Sclerosis
  01/29/2021 / 18:10 - GlobeNewswire
•  
• Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)
  01/26/2021 / 12:45 - GlobeNewswire
•  
• Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
  01/15/2021 / 20:17 - GlobeNewswire
•  
• Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
  01/13/2021 / 15:20 - GlobeNewswire
•  
• Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
  01/04/2021 / 20:00 - GlobeNewswire
•  
• Genmab Announces Enapotamab Vedotin Update
  11/24/2020 / 16:40 - GlobeNewswire
•  
• Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
  11/05/2020 / 14:38 - GlobeNewswire
•  
• Genmab Announces Financial Results for the First Nine Months of 2020
  11/04/2020 / 17:04 - GlobeNewswire
•  
• Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis
  10/21/2020 / 22:48 - GlobeNewswire
•  
• Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2020
  10/13/2020 / 12:41 - GlobeNewswire